Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effect on Cardiovascular Events in Type 2 Diabetes (Japan)
jRCT2080222423Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and cardiac morbidity comparing Dapagliflozin 10 mg once daily with Placebo once daily (2 arms). Primary endpoint: Primary composite cardiovascular endpoint. Started Mar 2014; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on jRCT2080222423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222423.